WADA anti-doping explained, and why the law decides it

A test result comes back, a name appears, and the coverage becomes an argument about pharmacology. Was the substance really performance-enhancing? Could a quantity that small have done anything at all? Almost none of the fight is actually about that. Anti-doping is a body of private law with a laboratory bolted on to it, and nearly every case that turns into a controversy turns on a legal question instead: who had to prove what, which organisation had jurisdiction, whether a deadline was met, whether a published procedure was followed to the letter. Getting WADA anti-doping explained properly means starting with the contract, not the urine sample.

The chemistry is the least contested part of the whole system. A modern accredited laboratory can identify a banned molecule at concentrations that would have been invisible a generation ago, and defences that attack the analysis itself succeed rarely. What athletes, lawyers and national federations actually argue about is everything wrapped around the analysis. That is where the inconsistency lives, and it is why two athletes who took the same substance in the same month can end up with completely different outcomes without anybody behaving improperly.

WADA anti-doping explained: the Code binds you by contract, not by law

The World Anti-Doping Agency was created in 1999, after a doping scandal at the Tour de France made it obvious that leaving each sport to police itself produced neither consistency nor credibility. The agency's central product is the World Anti-Doping Code, which first took effect in 2004 and has been revised at intervals since. The current version and its effective date are published by WADA, and every revision is preceded by a consultation running years rather than months.

Here is the thing most coverage skips. The Code is not a law anywhere. No parliament passed it. WADA cannot fine you, arrest you or stop you leaving a country. Its rules reach athletes through a chain of private agreements: an international federation adopts the Code, a national federation adopts the international federation's rules as a condition of membership, and an athlete accepts those rules by entering a competition or holding a licence. Sign the entry form and you have agreed to be tested, to file your location, to accept a particular tribunal and to accept a particular set of consequences.

That contractual foundation explains several things that look strange from outside. It explains why the penalty is exclusion from sport rather than a criminal one. It explains why an athlete who retires can, in some circumstances, place themselves outside the reach of the rules and why returning to competition requires re-entering the testing pool first. And it explains the single most persistent complaint about the system: an athlete has no realistic option to decline. You cannot compete at a serious level and refuse the Code. Consent that cannot be withheld is consent in name only, which is exactly the argument that has driven the human rights litigation around sports arbitration.

Governments could not sign a private instrument of this kind without creating awkward constitutional problems, so they were brought in a different way. UNESCO adopted the International Convention against Doping in Sport in 2005, which gives states a treaty instrument through which they commit to support the Code's principles in their own territory: funding a national anti-doping organisation, restricting the supply of doping substances, and cooperating with testing programmes. States are not signatories to the Code. They are parties to a convention that commits them to make the Code work.

Alongside the Code sit the International Standards, eight technical documents that carry the operational detail. The Prohibited List is one. The others cover testing and investigations, laboratories, therapeutic use exemptions, privacy and personal information, education, results management, and compliance by signatories. These are not appendices. A procedural failure against one of them is the most common route by which a case collapses, and they are drafted with that in mind.

• 11Anti-doping rule violations in Article 2
• 8International Standards under the Code
• 3Criteria for listing a substance
• 2How many of those must be met

Structural counts from the published World Anti-Doping Code and Program. These are counts of rules, not of cases or people.

The eleven rule violations in Article 2 are worth pausing on, because most people assume there is only one. Testing positive is the first. Using or attempting to use a prohibited substance is separate, and can be proved without any positive test. Then: refusing or evading sample collection, whereabouts failures, tampering with any part of the process, possession, trafficking, administering a substance to someone else, complicity, prohibited association with a person serving a ban, and acts intended to discourage or retaliate against someone reporting doping to the authorities. Several of these apply to coaches, doctors and agents rather than to athletes, and several have been used far more effectively than the positive-test route in the largest investigations.

Three layers of authority, and the gap where enforcement leaks

The most common misconception about the system is that WADA tests athletes. It does not, in the ordinary case. WADA writes the rules, accredits the laboratories, monitors whether signatories are complying, funds research, and holds a right of appeal in every case anywhere. The testing itself is done by somebody else.

Three kinds of organisation share the work, and the division between them is the origin of most of the inconsistency people complain about.

International federations run the anti-doping programme for their sport at international level. They decide who sits in the international testing pool, they collect samples at their own events, and in most sports they conduct results management for international-level athletes. Their capacity varies enormously. A federation with a large commercial income and a dedicated integrity unit is a different regulator from one run by a handful of staff.

National anti-doping organisations, such as UK Anti-Doping, run the programme within a country. They test national-level athletes, operate a domestic testing pool, and manage results for athletes under their jurisdiction. Their budgets come from public funding and are set by national governments with their own priorities, which is precisely why testing density is not remotely uniform across the world.

Major event organisers run their own programme for the duration of an event, which is why the testing regime at an Olympic Games is not the same one that applied to the same athlete the previous month.

Every one of these has adopted the same Code. None of them is a branch office of WADA. They are independent bodies that have contractually agreed to apply a common rulebook, and the difference between agreeing to apply a rule and applying it identically is where the whole argument sits.

The consequences are concrete. How often an athlete is tested depends on which country they live in and which sport they compete in. Whether intelligence about a suspicious pattern is pursued depends on whether the responsible organisation has investigators. Whether a case is charged at all depends on the judgement of the body doing results management. Two athletes in different sports can be subject to the same written rule and a completely different probability of ever being caught breaking it.

WADA's answer to this is the compliance regime. It monitors signatories against the standards, issues corrective action notices, and can declare an organisation non-compliant, which triggers consequences that can extend to a national federation losing the right to host events or its athletes competing under restrictions. That is real leverage. It is also slow, politically contested, and it operates on organisations rather than on the individual gaps that let a particular athlete go untested for a year. This tension between a global rulebook and locally funded enforcement is the same one that runs through the way international sport governs itself generally, and it is not close to being resolved.

There is one more structural fact worth stating plainly, because it does more to shape the politics of the system than anything else.

• Olympic Movement50.0%
• Governments and public authorities50.0%

WADA's core budget is met on an equal-partnership basis between the Olympic Movement and public authorities. The proportion, not any cash figure, is the point.

Show the numbers

Who funds the agency that writes the rules

Item	Value
Olympic Movement	50%
Governments and public authorities	50%

Half the money that funds the regulator comes from the sports movement being regulated, and half from governments whose own national teams are being tested. Both halves are represented on the board. Nobody has designed a better model, and the alternatives all fail on the same problem of who would pay instead. It remains, though, the first thing an athlete's lawyer points at when arguing that the system is not the neutral tribunal it claims to be.

What gets banned, and the two-out-of-three test that decides it

The Prohibited List is revised annually and published in advance of the year it applies to. It is a document of a few pages, organised by category rather than by an exhaustive list of molecules, and that structure matters more than it appears to.

Substances are grouped by whether they are prohibited at all times or only in competition, and by class: anabolic agents, peptide hormones and growth factors, beta-2 agonists, hormone and metabolic modulators, diuretics and masking agents, stimulants, narcotics, cannabinoids, glucocorticoids and beta-blockers, plus prohibited methods covering blood manipulation, physical or chemical tampering with samples, and gene doping. Most categories close with a phrase covering other substances with a similar chemical structure or similar biological effect. That catch-all clause exists because the alternative is a list that is obsolete the moment a chemist alters one bond in a molecule to produce something with the same effect and a different name.

For a substance to be considered for the list, WADA must determine that it meets at least two of three criteria set out in Article 4.3.1:

• there is medical or other scientific evidence, pharmacological effect or experience that it has the potential to enhance, or does enhance, sport performance;
• its use represents an actual or potential health risk to the athlete;
• WADA determines that its use violates the spirit of sport as described in the introduction to the Code.

Two of three. Not all three. A substance that does nothing for performance can still be banned if it is dangerous and offends the spirit of sport. A substance that carries no health risk can be banned if it enhances performance and offends the spirit of sport. Masking agents and substances that hide the use of something else are listed on a separate basis, because their whole function is to defeat the detection system.

The third criterion is where the philosophical argument lives, and the honest thing to say is that it is not a scientific test at all. The spirit of sport is described in the Code through a list of values: health, ethics, fair play, excellence in performance, character, respect for rules and for other participants, courage, community. Reasonable people disagree about whether a given substance offends any of them. Recreational drugs with no plausible performance benefit have been the sharpest test of this, because they are on the list largely on health and spirit-of-sport grounds, and an athlete sanctioned for one out of competition has a strong intuitive case that anti-doping has strayed outside its purpose.

Two further categories change how cases run. Specified substances are ones more likely to have been consumed for a purpose other than enhancing performance, or more likely to appear in a legitimate medicine, and their classification shifts the burden around when the sanction is calculated. Substances of abuse, a category the Code addresses separately, are certain recreational drugs, and where an athlete can establish that use occurred out of competition and was unrelated to sport performance, the Code provides a much shorter route through the sanction. Neither category makes a substance legal. Both change who has to prove what once it has been found.

There is also a Monitoring Programme, a list of substances that are not prohibited but are being watched for patterns of misuse. Substances have moved from the monitoring programme onto the list once the data justified it. It is the closest thing anti-doping has to an early warning system.

Strict liability is the whole system in one sentence

If you understand nothing else about how the rules work, understand this. Under Article 2.1, an anti-doping rule violation is committed when a prohibited substance is found in an athlete's sample. That is the entire test. Intent is not an element. Knowledge is not an element. Negligence is not an element. It is the athlete's personal duty to ensure that no prohibited substance enters their body, and the Code says so explicitly.

Strict liability is not an accident of drafting or a piece of institutional harshness. It exists because the alternative is unworkable. If intent had to be proved, every case would turn on the athlete's account of their own state of mind, which is unfalsifiable, and the practical consequence would be that no case could ever be proved against a competent liar. A rule requiring proof of intent would protect exactly the athletes it was meant to catch, because sophisticated doping programmes are designed to produce plausible innocent explanations.

The cost is equally real. Strict liability catches the innocent alongside the guilty. Contaminated supplements are a genuine and documented problem, meat contamination has produced findings in some countries, and prescribed medication taken on the advice of a doctor who did not check the list has ended careers. In every one of those situations the athlete has committed a rule violation. There is no arguing about it.

What the Code does instead is separate the two questions completely. Whether a violation occurred is answered by strict liability, without reference to fault. What the consequence should be is answered afterwards, and there fault is close to the only thing that matters. This split is the source of the sentence that confuses more readers than any other in the field: an athlete can be found to have broken the anti-doping rules and receive no ban at all.

It is also why the language in reporting is so often wrong. An adverse analytical finding is a laboratory result. An anti-doping rule violation is a legal conclusion reached after the process has run. They are not the same event and can be separated by a year or more.

Therapeutic use exemptions and the question they are built to answer

Athletes get ill. Some of them have chronic conditions treated with drugs that appear on the list, and a rule that forced them to choose between competing and being treated would be indefensible. The therapeutic use exemption is the mechanism that resolves this, and it is genuinely difficult to administer.

An exemption is granted by a panel of physicians, applying the conditions set out in the International Standard for Therapeutic Use Exemptions. All of them must be met. The substance must be needed to treat a diagnosed condition supported by relevant clinical evidence. Its therapeutic use must be highly unlikely to produce any additional enhancement of performance beyond a return to the athlete's normal state of health. There must be no reasonable permitted alternative. And the necessity must not itself be a consequence of earlier use of a substance that was prohibited at the time it was taken, which closes an obvious loop.

The second condition is the hard one. Restoring an athlete to normal health is permitted. Improving them beyond it is not. The line is easy to state and genuinely difficult to draw in a body that has been training at the limit for a decade, and it is why exemption decisions in some therapeutic areas attract far more scrutiny than others.

Applications are normally made in advance and reviewed by the committee of the organisation with jurisdiction, which will be an international federation for an international-level athlete and a national anti-doping organisation otherwise. Retroactive exemptions are possible in defined circumstances, such as emergency treatment or where there was insufficient time to apply before a sample was collected. WADA can review a granted exemption and reverse it, and can review a refusal. Either outcome can be appealed.

The privacy dimension is worth naming. A granted exemption is confidential medical information about a named individual, held in a database, accessible to several organisations across several countries. When exemption records have been published without consent as a result of database intrusions, the damage was not sporting. It was the disclosure of private diagnoses that the athletes concerned had never chosen to make public. The International Standard for the Protection of Privacy and Personal Information exists precisely because the anti-doping system is one of the largest sustained collections of athlete medical data anywhere, and it collects that data from people who cannot decline to provide it.

Whereabouts: one hour a day, and the objection nobody has answered

Testing at a competition catches almost nothing worth catching. Many of the substances that actually change what an athlete can do are used during training blocks, weeks or months before an event, and are cleared long before anybody lines up. An anti-doping system that only tested at events would be theatre.

That is why out-of-competition testing with no advance notice exists, and it is why whereabouts requirements exist, because a tester who cannot find an athlete cannot test them.

Athletes placed in a registered testing pool file information every quarter through the ADAMS database: overnight address, training locations and schedule, competition schedule, and one 60-minute window each day, at a specified address, during which they undertake to be available. The window sits within defined daytime hours. Athletes update it as plans change, and many do so from a phone, repeatedly, for years.

Two things can go wrong. A filing failure is a failure to file accurate and complete information, or to update it when it changes. A missed test is a failure to be available at the declared location during the declared window when a tester attends. Any combination of three within twelve months is itself an anti-doping rule violation under Article 2.4, sanctioned in its own right, with the length turning on the athlete's degree of fault.

Each individual failure has to be recorded through a defined procedure before it counts, including notice to the athlete and an opportunity to respond, and those procedural requirements are litigated far more often than the underlying facts. A missed test is frequently defended not by disputing the absence but by showing that the tester's attempt or the subsequent record did not meet the standard.

The objection to the whole regime is not frivolous and it has never really been answered. No other profession requires its members to disclose their location to a regulator every day of the year, including days they are not working, including holidays, including nights spent at an address that belongs to somebody else. The obligation falls on the athlete's household as much as on the athlete. It runs during injury and during the off-season. It is enforced by people arriving unannounced at a private home at hours most people would consider intrusive.

The system's defence is straightforward: without it, out-of-competition testing does not function, and without out-of-competition testing the entire programme collapses into a formality. That is true. It is also true that the cost of the trade falls entirely on the athletes, and the largest share of it on athletes who have never taken anything. Both statements can be held at once, which is what makes this the most durable criticism of the model.

From the knock on the door to the B sample

The collection procedure is set out in granular detail in the International Standard for Testing and Investigations, and the detail is the point. Every step is written down because every step has been challenged.

An athlete is notified in person by a doping control officer or a chaperone, who identifies themselves and explains the athlete's rights and responsibilities. From that moment the athlete is under continuous observation until the sample is provided. The reason is not suspicion of the individual; it is that an unobserved interval is a hole in the chain of custody that any competent lawyer will drive through.

The athlete may be permitted to complete a training session or a medal ceremony, with the chaperone present throughout. Delay itself is not a violation, but leaving observation is where refusing or evading collection begins, and an evasion charge under Article 2.3 carries consequences comparable to a positive test. Athletes have received longer sanctions for what happened around a test than they would have received for the substance the test was looking for.

The sample is provided under direct observation by an officer of the same gender. The athlete selects a sealed collection kit from a selection offered, checks it, and divides the sample between an A bottle and a B bottle. Volume and, for urine, suitability for analysis are checked against the standard, with a defined partial-sample procedure where the first attempt is insufficient. The athlete seals the bottles themselves. The paperwork records the kit numbers, the medications and supplements declared, and any comment the athlete wishes to make about the process, and the athlete signs it. That signature is the reason irregularity complaints raised months later are so often unsuccessful.

Samples travel to a WADA-accredited laboratory, which is told nothing about whose sample it is analysing. The laboratory tests the A sample. If it reports an adverse analytical finding, the athlete is notified and has the right to request analysis of the B sample, to attend or be represented at the opening, and the B result must confirm the A. If it does not, the case ends there.

Blood collection follows a parallel procedure with its own requirements, including a rest period before collection. Dried blood spot collection has been brought within the standards, which lowers the logistical cost of testing in places where transporting frozen blood is impractical. Samples can also be stored and reanalysed later as detection methods improve, within the ten-year limitation period the Code sets. That last point does real work as a deterrent: a substance that is undetectable this year may not be undetectable in six years, and the sample will still be in a freezer.

The biological passport looks for the effect, not the drug

Direct detection has an obvious limit. It can only find a substance that is still present and that somebody has developed an assay for. Micro-dosed substances clear quickly, some are identical to what the body makes naturally, and a new molecule is invisible until a method exists to see it.

The athlete biological passport attacks the problem from the other end. Instead of looking for the drug, it monitors the athlete's own biological markers over time and looks for changes that doping would produce and normal physiology would not.

There are two established modules. The haematological module tracks blood markers associated with oxygen transport, which is what blood transfusions and substances stimulating red cell production are designed to alter. The steroidal module tracks the profile of naturally occurring steroid hormones and their ratios in urine, which is what synthetic testosterone and related compounds disturb.

The statistical machinery is the interesting part. Each athlete's readings build an individual reference range using an adaptive model that narrows as more samples arrive. The comparison is not against a population norm; it is against that athlete's own established profile, with expected variation accounted for. A value that would be unremarkable in the general population can be a clear anomaly for an individual whose own baseline sits elsewhere.

When the model flags a profile, it goes to an athlete passport management unit and then to independent experts, typically three, who review it separately and must reach a unanimous view that no normal physiological or pathological explanation accounts for the pattern before a case proceeds. The athlete is given the opportunity to explain, and explanations such as altitude exposure, illness or blood loss are considered as part of that review.

Passport evidence supports a charge of use under Article 2.2 rather than presence under Article 2.1. There is no substance to point at. The evidence is a pattern, presented by experts, and the tribunal decides whether it meets the required standard. This changed detection substantially, because it removed the assumption that avoiding a positive test is the same as avoiding detection, and it made the total volume of samples collected from an athlete valuable in itself rather than only when one of them came back positive. The long arms race between concealment methods and detection methods, which is the whole history of doping in endurance sport, is the reason the passport was built at all.

Results management, provisional suspension, and who has to prove what

Once a finding exists, the process becomes recognisably legal. The organisation with results management authority reviews whether there is a valid exemption, whether there was any apparent departure from the standards that would explain the result, and whether to proceed. If it does proceed, the athlete receives a notice setting out the alleged violation, the evidence, the potential consequences and the athlete's rights.

A provisional suspension may follow immediately. It is mandatory where the finding involves a substance that is not a specified substance, and discretionary in other cases. The athlete may request an expedited hearing on the provisional suspension itself, before the merits are decided.

The provisional suspension is where the sharpest injustice in the whole system sits, and it is structural rather than anyone's fault. An athlete who is eventually cleared may have missed an entire season, or a championship that comes round once every four years, while a case that ultimately went nowhere was resolved. Time served counts against any eventual sanction. It cannot count against a final that has already been contested. The system chose the risk of suspending the innocent over the risk of letting the guilty compete, and the choice is defensible, but it is a choice with victims.

Two burdens of proof operate, and confusing them is the source of a great deal of bad commentary.

The anti-doping organisation must establish the violation to the comfortable satisfaction of the hearing panel, a standard the Code places above the balance of probabilities and below proof beyond reasonable doubt, and which rises with the seriousness of the allegation. Where the athlete has to prove something, such as how a substance entered their body, the standard is the ordinary balance of probabilities.

There are also presumptions. A WADA-accredited laboratory is presumed to have conducted analysis in accordance with the laboratory standard. An athlete who wants to displace that presumption must show a departure from the standard that could reasonably have caused the finding, at which point the burden shifts back to the organisation to establish that the departure did not cause it. This is not a technicality that makes cases unwinnable. It is a rule about who moves first, and moving first is expensive.

That expense is the quiet inequality running through the whole system. Mounting a serious defence requires specialist legal representation, independent scientific expert evidence, and often laboratory work of the athlete's own to identify a contamination source. An athlete with a large sponsorship income and a federation prepared to help can do all of it. An athlete on a small national grant frequently cannot, and accepts an outcome they might have successfully contested. The Code applies identically to both. The ability to use it does not.

1. 1Notification and collectionA doping control officer identifies themselves and notifies the athlete, who is kept under continuous observation until the sample is given, split into A and B bottles and sealed by the athlete personally.
2. 2The laboratory reports the A sampleAn accredited laboratory analyses the A sample without knowing whose it is, and reports any adverse analytical finding to the organisation with results management authority and to WADA.
3. 3Initial reviewThe organisation checks for a valid therapeutic use exemption and for any apparent departure from the testing or laboratory standards that would explain the finding. A case can end here with no charge and no publicity.
4. 4Notice and provisional suspensionThe athlete is formally charged and told the evidence and the possible consequences. A provisional suspension is mandatory for non-specified substances, and the athlete may request an expedited hearing on it.
5. 5The B sampleThe athlete may require the B sample to be analysed and may attend the opening. If the B does not confirm the A, the case is closed. If it does, the analytical evidence is settled.
6. 6Explanation and hearingThe athlete may accept the consequences or contest them before a hearing panel. The organisation must prove the violation to the panel's comfortable satisfaction; the athlete proves any defence on the balance of probabilities.
7. 7Fault is assessed and a sanction setThe panel decides the period of ineligibility using the Code's ranges, adjusted for intent, degree of fault, contaminated products, prompt admission and any substantial assistance given to investigators.
8. 8AppealThe athlete, the anti-doping organisation, the international federation and WADA may all appeal. The Court of Arbitration for Sport rehears the case in full and its award is challengeable in the Swiss courts only on very narrow grounds.

The generic route under the Code. Timings vary by organisation and by sport, and the appeal stage may involve an intermediate national body before reaching CAS.

Sanctions, and how intent, contamination and cooperation move them

The Code sets ranges, not fixed penalties, and the movement within the ranges is where all the perceived inconsistency comes from.

The starting point for a first violation involving presence, use or possession is four years where the substance is not a specified substance, unless the athlete establishes that the violation was not intentional. Where it was not intentional, the starting point is two years. For a specified substance, the position is reversed: the starting point is two years unless the anti-doping organisation establishes that the violation was intentional, in which case it is four.

That flip is the single most consequential sentence in the sanctioning provisions, and it is why the classification of a substance matters so much to an athlete's lawyer.

From the applicable starting point, several provisions move the number.

No Fault or Negligence eliminates the period of ineligibility entirely. It requires the athlete to establish that they did not know or suspect, and could not reasonably have known or suspected even with the utmost caution, that they had used the substance. The bar is deliberately close to unreachable, and it is met rarely.

No Significant Fault or Negligence reduces it. Where the substance was a specified substance or came from a contaminated product, the range runs from a reprimand with no ban up to two years, depending on the athlete's degree of fault. In other cases the reduction cannot take the sanction below half the otherwise applicable period. A contaminated product is defined as one containing a prohibited substance that is not disclosed on the label or in a reasonable internet search, which places a real research obligation on the athlete before they swallow anything.

Substantial assistance allows a suspension of part of the sanction where an athlete provides information that leads to a case being brought against somebody else, with WADA's approval required and a defined limit on how much of the sanction can be suspended. This is the provision that turns an individual case into an investigation, and it is how several of the largest networks were exposed. It is also, straightforwardly, a plea bargain, with the moral awkwardness that comes with one: the athlete who knows the most about a doping programme has the most to trade.

Prompt admission allows a reduction where an athlete admits the violation quickly after being notified, within a short window set by the Code and with the agreement of WADA and the organisation. Aggravating circumstances and repeat violations move in the other direction, with a second violation calculated by a formula rather than a fixed figure.

• Lowest in range
• Highest in range

Intentional, non-specified substance44

Not intentional22

Three whereabouts failures12

No Significant Fault, contaminated product02

No Fault or Negligence00

Ranges as structured by the Code for a first violation. The final figure inside each range depends on the panel's assessment of the athlete's degree of fault. Substantial assistance and prompt admission can reduce these further; aggravating circumstances and repeat violations increase them.

Show the numbers

Where a first violation lands, in years, before any further reduction

Item	Lowest in range	Highest in range
Intentional, non-specified substance	4	4
Not intentional	2	2
Three whereabouts failures	1	2
No Significant Fault, contaminated product	0	2
No Fault or Negligence	0	0

Take a constructed example, with no real athlete or product behind it. An athlete buys an over-the-counter recovery supplement from a mainstream retailer, checks the label, finds nothing prohibited on it, and tests positive for a specified substance months later. Strict liability means the violation is established the moment the finding is confirmed. The starting point is two years, because the organisation cannot show intent. The athlete then obtains an analysis of a sealed tub from the same batch showing the substance was present and undeclared, which establishes a contaminated product. That opens the reprimand-to-two-years range, and where the athlete lands inside it depends on what they did before taking it: whether they used a supplement testing scheme, whether they consulted their team doctor, whether they searched the product, whether they had been warned about that category of product before. Two athletes with identical test results and different levels of diligence get different answers, and the system regards that as the rule working rather than failing.

The consequences reach beyond the ban itself. Results from the date of sample collection onwards are normally disqualified, with medals, points and prize money forfeited. During ineligibility the athlete cannot participate in any capacity in any sport under a signatory's authority, which excludes coaching and, in most cases, training with a member club. Where an athlete has an individual contract, a doping sanction will usually trigger termination or suspension clauses in it, and the financial consequences of that frequently exceed the sporting ones. Team-mates and relay partners lose results they had no part in causing.

WADA anti-doping explained at the appeal stage: what CAS actually does

Appeals under the Code go to the Court of Arbitration for Sport for international-level athletes and for cases arising from international events. National-level athletes may have an intermediate national appeal body first, and a right of appeal to CAS from there depending on the applicable rules. WADA has a right of appeal in every case, which is the mechanism by which decisions perceived as too lenient at national level get reviewed. It is used, and its existence changes how national tribunals decide.

The most important feature of a CAS appeal is that it is a full rehearing. The panel is not confined to reviewing whether the first tribunal made an identifiable error. It hears the case again, on the evidence put before it, and substitutes its own decision. That is unusual for an appellate body and it has a specific consequence: new evidence and new arguments can be introduced, and an athlete who lost badly at first instance is not necessarily arguing uphill.

The panel is normally three arbitrators, chosen from a closed list maintained by the court, with each party appointing one and the president appointed by the court. The seat of the arbitration is in Lausanne, which fixes Swiss procedural law as the framework regardless of where the hearing physically takes place. An award can be challenged before the Swiss Federal Tribunal only on narrow grounds such as a defect in the constitution of the panel, a violation of the right to be heard, or incompatibility with public policy. Those challenges very rarely succeed. For practical purposes, CAS is the end.

The system has been tested against European human rights law, and the outcome shaped how it now operates. Where an athlete has no genuine choice but to accept arbitration, the tribunal has to meet fair-trial guarantees, including a public hearing where one is requested. The court's practice on public hearings changed as a result. The deeper criticism, that a closed list of arbitrators and a funding structure connected to the sports movement creates at minimum an appearance problem, has not gone away. Both the strengths of the model, which are speed, specialist expertise and a single consistent body of decisions across every sport, and its weaknesses run through how sport's own supreme court operates in every kind of dispute, not only doping.

The honest limits, and what the system is actually good at

An explanation that stopped here would be flattering and incomplete. Four limits are worth stating plainly.

Detection windows. Many substances are detectable for a period measured in days after use, sometimes shorter with careful micro-dosing. An athlete who knows the clearance profile, doses in a training block and is not tested during the window is not caught by direct analysis at all. This is the whole reason the biological passport, intelligence gathering and long-term sample storage exist, and it is why the number of tests conducted is a poor measure of a programme's quality. Timing and targeting matter more than volume.

Funding disparity. Testing costs money that comes from national budgets and federation income, both of which vary by more than an order of magnitude between countries. Athletes competing in the same final may have arrived from anti-doping programmes with completely different capabilities. The rule applying to them is identical. The chance of it having been enforced against them is not. This is the largest unfairness in the system and it cannot be fixed by better drafting.

The system catches the careless more reliably than the sophisticated. An organised programme with medical supervision, knowledge of clearance times, access to substances that are hard to distinguish from endogenous ones and the discipline to time everything around a known testing schedule is a genuinely hard target. A lone athlete who bought the wrong supplement is an easy one. The published caseload therefore over-represents error and under-represents design, and any inference from the case list to the actual prevalence of doping runs straight into that bias.

Enforcement depends on institutions that have their own interests. Every body in the chain has some reason to prefer that its own athletes are not found to be doping. That does not mean corruption, and in most cases it means nothing at all. It does mean the compliance and appeal mechanisms exist for a reason, and that WADA's right of appeal in every case is not a formality.

What the system is genuinely good at is worth stating too, because the cynical reading is also incomplete. It produced a single rulebook where there had been dozens. It made a sanction imposed in one sport in one country recognised everywhere else, which is what stops a banned athlete simply moving. It created an evidential standard and a laboratory network capable of meeting it. It built a body of published decisions that makes outcomes predictable in a way they were not before. Anti-doping before 1999 was a set of unconnected, unevenly applied national and federation rules, and whatever the current model's faults, nobody proposing to abolish it has explained what would replace it. The same harmonisation problem, and the same difficulty of applying one written standard consistently across very different bodies, shows up wherever sport tries to classify people rather than performances, whether in the classification system that underpins Paralympic sport or in the eligibility rules governing transgender athletes.

How to read a doping case in the news

Most reporting on a doping case gives you the substance and the ban length and stops. Those are the two least informative facts available. Six questions turn a headline back into something you can actually assess.

Which rule violation is alleged? Presence under Article 2.1 is a laboratory finding. Use under 2.2 may rest entirely on passport or documentary evidence with no positive test at all. Evasion, tampering and prohibited association are different cases with different proof requirements. A story that says only "failed a drugs test" has usually not established which of these it means.

Which organisation is running it, and which rules apply? International federation, national anti-doping organisation or event organiser. This determines the tribunal, the appeal route and the timetable, and it is the first thing that explains why an apparently similar case elsewhere took a different course.

Was the substance specified or not, and was it prohibited in competition only? This single classification decides who has to prove intent, which decides where the sanction starts. It is the most consequential fact in most cases and it appears in almost no reporting.

What stage has been reached? An adverse analytical finding is not a violation. A provisional suspension is not a ban. A first-instance decision is not final while an appeal window is open, and WADA can appeal a decision that everyone else has accepted. Cases are routinely reported as concluded at three separate points.

What was the finding on fault, and what moved the sanction? A ban shorter than the standard starting point means the panel found something: no significant fault, a contaminated product, substantial assistance, a prompt admission. A ban longer than it means the panel found intent or aggravating circumstances. The number on its own tells you nothing; the reason for the number tells you everything.

Who could still appeal, and by when? Until every appeal right has expired, the outcome is provisional, however final the coverage sounds.

Ask those six and the pattern that looks like inconsistency mostly resolves into a system doing what it was written to do, applied by organisations of very unequal capability, to athletes of very unequal means. That is a fair criticism of the system, and it is a different criticism from the one usually made. The rules are not the problem. Who can afford to use them, and who has the resources to enforce them, is.

More explanations of the rules and institutions that sit behind every sport covered here are collected in the multi-sport archive.